| Kathleen Urban Dehorn, MD | |
|
2505 East Paris Ave Se Ste 100, Grand Rapids, MI 49546-6100 | |
| (616) 285-1200 | |
| (616) 940-0864 |
| Full Name | Kathleen Urban Dehorn |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 20 Years |
| Location | 2505 East Paris Ave Se Ste 100, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215143797 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 258069 (New York) | Secondary |
| 207W00000X | Ophthalmology | 4301083642 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vitreo-retinal Associates P.c. | 3072525278 | 5 |
News Archive
Diverse local authority policies and practices throughout the UK are making big differences to the uptake and operation of 'direct payments' - a system for supporting people who are receiving community care by enabling them to 'purchase' their own care.
Exposure to elevated levels of carbon monoxide in utero increases infants' risk of poor lung function at one month after birth, according to new research conducted as part of the Ghana Randomized Air Pollution and Health Study.
A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the "polypill": a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).
Two University of Birmingham academics are calling for more research to be carried out looking at how the brains of sportspeople - including children - react when they receive a blow to the head.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 8 days ago
| Entity Name | Vitreo-retinal Associates P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710913926 PECOS PAC ID: 3072525278 Enrollment ID: O20060706000091 |
News Archive
Diverse local authority policies and practices throughout the UK are making big differences to the uptake and operation of 'direct payments' - a system for supporting people who are receiving community care by enabling them to 'purchase' their own care.
Exposure to elevated levels of carbon monoxide in utero increases infants' risk of poor lung function at one month after birth, according to new research conducted as part of the Ghana Randomized Air Pollution and Health Study.
A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the "polypill": a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).
Two University of Birmingham academics are calling for more research to be carried out looking at how the brains of sportspeople - including children - react when they receive a blow to the head.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathleen Urban Dehorn, MD 2505 E Paris Ave Se Ste 100, Grand Rapids, MI 49546-6100 Ph: (616) 285-1200 | Kathleen Urban Dehorn, MD 2505 East Paris Ave Se Ste 100, Grand Rapids, MI 49546-6100 Ph: (616) 285-1200 |
News Archive
Diverse local authority policies and practices throughout the UK are making big differences to the uptake and operation of 'direct payments' - a system for supporting people who are receiving community care by enabling them to 'purchase' their own care.
Exposure to elevated levels of carbon monoxide in utero increases infants' risk of poor lung function at one month after birth, according to new research conducted as part of the Ghana Randomized Air Pollution and Health Study.
A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the "polypill": a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).
Two University of Birmingham academics are calling for more research to be carried out looking at how the brains of sportspeople - including children - react when they receive a blow to the head.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 8 days ago
Dr. Laura J Piippo, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 750 E Beltline Ave Ne, Grand Rapids, MI 49525 Phone: 616-949-2600 Fax: 616-365-2076 | |
Melissa Lynn Meldrum, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2757 Leonard St Ne, Suite 300, Grand Rapids, MI 49525 Phone: 616-942-6687 Fax: 616-942-9797 | |
Dr. Mark Owen Moleski, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 791 Kenmoor Se, Suite A Cascade Ophthalmology Pc, Grand Rapids, MI 49546 Phone: 616-575-8200 Fax: 616-954-9622 | |
Dr. Robert J Roosenberg, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 750 E Beltline Ave Ne, Grand Rapids, MI 49525 Phone: 616-949-2600 Fax: 616-365-2076 | |
Greg Bever, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5030 Cascade Rd Se, Grand Rapids, MI 49546 Phone: 616-954-2020 | |
Dr. Mark E Sheldon, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 750 E Beltline Ave Ne, Grand Rapids, MI 49525 Phone: 616-949-2600 Fax: 616-365-2076 | |
Dr. Tiffany Lauren Kent, MD, PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4070 Lake Dr Se, Suite 205, Grand Rapids, MI 49546 Phone: 616-888-2948 Fax: 616-888-2949 |